Sagent Pharmaceuticals, Inc. (SGNT) is a specialty pharmaceutical company that develops, manufactures, and markets pharmaceutical products. The company focuses on injectable products primarily in the areas of anti-infective, oncology, and critical care. Its products are marketed in the United States and internationally to hospitals, long-term care facilities, and alternate site facilities. Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, Illinois.
In 2016, Sagent Pharmaceuticals was acquired by Nichi-Iko Pharmaceutical Co. Ltd., a Japan-based generic drug maker, for approximately $736 million. Following the acquisition, Sagent Pharmaceuticals became a wholly-owned subsidiary of Nichi-Iko Pharmaceutical.
As a private subsidiary of Nichi-Iko Pharmaceutical, Sagent Pharmaceuticals' financial information is not publicly available.
Sagent Pharmaceuticals, Inc. (SGNT) is a specialty pharmaceutical company that develops, manufactures, and markets pharmaceutical products. The company focuses on injectable products primarily in the areas of anti-infective, oncology, and critical care. Its products are marketed in the United States and internationally to hospitals, long-term care facilities, and alternate site facilities. Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, Illinois.